Comparative efficacy of ciltacabtagene autoleucel (cilta-cel) versus belantamab mafodotin (belamaf), bortezomib, and dexamethasone and versus belamaf, pomalidomide, and dexamethasone in patients with relapsed / refractory multiple myeloma (RRMM) previously treated with 1–3 prior lines of therapy using a matching-adjusted indirect comparison
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Christopher Strouse, Surbhi Sidana, Rafael Fonseca, Joaquin Martinez-Lopez, Yaël Cohen, Binod Dhakal, Murali Janakiram, Suzy Van Sanden, João Mendes, Joris Diels, Seina Lee, Sundar Jagannath
Institutions: University of Iowa, Stanford Medicine, Stanford University, Mayo Clinic in Arizona, Hospital Universitario 12 De Octubre, Tel Aviv University, Tel Aviv Sourasky Medical Center, Medical College of Wisconsin, City Of Hope National Medical Center, Johnson & Johnson (United States), Icahn School of Medicine at Mount Sinai
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7108452572
Cites:
Cited by:
Related to: